Abstract
AbstractThe development of a safe and effective Zika virus (ZIKV) vaccine has become a global health priority since the widespread epidemic in 2015-2016. Based on previous experience in using the well-characterized and clinically proven dengue virus serotype-2 (DENV-2) PDK-53 vaccine backbone for live-attenuated chimeric flavivirus vaccine development, we developed chimeric DENV-2/ZIKV vaccine candidates optimized for growth and genetic stability in Vero cells. These vaccine candidates retain all previously characterized attenuation phenotypes of the PDK-53 vaccine virus, including attenuation of neurovirulence for 1-day-old CD-1 mice, absence of virulence in interferon receptor-deficient mice, and lack of transmissibility in the main mosquito vectors. A single DENV-2/ZIKV dose provides protection against ZIKV challenge in mice and rhesus macaques. Overall, these data indicate that the ZIKV live-attenuated vaccine candidates are safe, immunogenic and effective at preventing ZIKV infection in multiple animal models, warranting continued development.
Funder
CDC intramural research fund and CDC-Takeda CRADA #D-33-16 fund
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference57 articles.
1. Petersen, L. R., Jamieson, D. J., Powers, A. M. & Honein, M. A. Zika virus. N. Engl. J. Med. 374, 1552–1563 (2016).
2. Musso, D., Ko, A. I. & Baud, D. Zika virus infection - after the pandemic. N. Engl. J. Med. 381, 1444–1457 (2019).
3. WHO Zika epidemiology update, https://www.who.int/emergencies/diseases/zika/zika-epidemiology-update-july-2019.pdf?ua=1 (2019).
4. Pattnaik, A., Sahoo, B. R. & Pattnaik, A. K. Current status of Zika virus vaccines: successes and challenges. Vaccines 8, https://doi.org/10.3390/vaccines8020266 (2020).
5. Baldwin, W. R. et al. Purified inactivated Zika vaccine candidates afford protection against lethal challenge in mice. Sci. Rep. 8, 16509 (2018).